Vancouver, Canada – July 4, 2023 – THC BioMed Intl Ltd. (“THC BioMed” or the “Company“) (THC.CSE, THCBF – OTC, TFHD.F), a leading player in the Canadian cannabis market, is excited to announce the release of its summer product line, featuring the THC Kiss Strawberry Tangerine Gummies with 10% THC.
The launch of these full-spectrum cannabis gummies represents the Company’s commitment to product innovation and diversification. We continue to work diligently to improve shareholder value and attract investor interest in the rapidly evolving cannabis market.
“Our new THC Kiss Strawberry Tangerine Gummies are the perfect addition to our product line for the summer season,” said John Miller, CEO of THC BioMed. “Crafted with the finest ingredients, these gummies reflect our dedication to quality, consistency, and customer satisfaction. We are optimistic that this launch will continue to position THC BioMed as a frontrunner in the cannabis product market. “
The THC Kiss Strawberry Tangerine Gummies are full-spectrum cannabis products, made with the purest ingredients, promising consumers a superior experience.
This product launch underlines THC BioMed’s ongoing efforts to expand its product portfolio and meet consumer demand for innovative, high-quality cannabis products.
For more information, media inquiries, or partnership opportunities, please contact:
President and CEO: John Miller THC BioMed Intl Ltd. T: 1-844-THCMEDS E: info@thcbiomed.com
About THC BioMed
As a leader in the Canadian cannabis industry, THC BioMed is licensed to cultivate and sell an extensive range of cannabis products. Its dedication to product development, scientific research, and fostering a diverse cannabis industry distinguishes the Company as a top player within the sector.
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC BioMed. Forward-looking information is based on certain key expectations and assumptions made by the management of THC BioMed. In some cases, you can identify forward-looking statements using words such as “will,” “may,” “would,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “could” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements in this release include that this launch will continue to position THC BioMed as a frontrunner in the cannabis product market. Forward-looking statements in this release are made as of the date of this press release and include that THC BioMed will be on the forefront of this rapidly growing industry. Although THC BioMed believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC BioMed can give no assurance that they will prove to be correct. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.